SPHERE - Study of Perinatal, paediatric and adolescent Health : Epidemiological Research and Evaluation
Equipe constitutive du CERPOP, UMR1295, unité mixte de recherche Inserm – Université Toulouse III Paul Sabatier
Isabelle LACROIX •  chercheure


 

2023
  1. Benevent J, Araujo M, Beau AB, Sicard D, Sommet A, Hurault-Delarue C, Lacroix I, Damase-Michel C. First trimester pregnancy exposure to fosfomycin and risk of major congenital anomaly: a comparative study in the EFEMERIS database. Infection. 2023 Feb;51(1):137-146. doi: 10.1007/s15010-022-01861-4.
2022
  1. Araujo M, Hurault-Delarue C, Sommet A, Damase-Michel C, Lacroix I. Topical sertaconazole during pregnancy and risk of adverse pregnancy outcome and major congenital anomalies: Comparative study in the EFEMERIS database. Mycoses. 2022 Apr;65(4):481-489. doi: 10.1111/myc.13422.
  2. Balon M, Tessier S, Damase-Michel C, Cottin J, Lambert A, Thompson MA, Benevent J, Lacroix I. Adverse drug reactions in pregnant women: Do they differ from those in non-pregnant women of childbearing age? Therapie. 2022 Nov 28:S0040-5957(22)00268-2. doi: 10.1016/j.therap.2022.11.005. Epub ahead of print.
  3. Benevent J, Hurault-Delarue C, Araujo M, Revet A, Sommet A, Lacroix I, Damase-Michel C. Prenatal Drug Exposure in Children With a History of Neuropsychiatric Care: A Nested Case-Control Study. Front Psychiatry. 2022 Mar 22;13:795890. doi: 10.3389/fpsyt.2022.795890.
  4. Vabre C, Araujo M, Damase-Michel C, Hurault-Delarue C, Lacroix I. Initial data on the safety of metopimazine during pregnancy and the risk of major birth defects and pregnancy loss - An observational study using the EFEMERIS database. Therapie. 2022 Jul-Aug;77(4):405-412. doi: 10.1016/j.therap.2021.09.006.

2021
  1. Araujo M, Hurault-Delarue C, Sommet A, Damase-Michel C, Benevent J, Lacroix I. Drug prescriptions in French pregnant women between 2015 and 2016: A study in the EGB database. Therapie. 2021 May-Jun;76(3):239-247. doi: 10.1016/j.therap.2020.07.002.
     
  2. Araujo M, Vabre C, Benevent J, Sommet A, Damase-Michel C, Hurault-Delarue C, Lacroix I. Risk of Pregnancy Termination and Congenital Anomalies After Domperidone Exposure: A Study in the EFEMERIS Database. Drug Saf. 2021 Jul;44(7):787-796. . doi: 10.1007/s40264-021-01077-9.
     
  3. Cottin J, Benevent J, Khettar S, Lacroix I. COVID-19 vaccines and pregnancy: What do we know? Therapie. 2021 Jul-Aug;76(4):373-374. doi: 10.1016/j.therap.2021.05.011.
     
  4. Hurault-Delarue C, Araujo M, Vabre C, Benevent J, Damase-Michel C, Lacroix I. What changes in prescription patterns of antiemetic medications in pregnant women in France ? Fundam Clin Pharmacol. 2021 Dec;35(6):1159-1167. doi: 10.1111/fcp.12681.
     
  5. Lacroix I, Hurault-Delarue C, Viard D, Revol B, Chaalel L, Damase-Michel C. Use of triptans during pregnancy? With caution! Therapie. 2021 Sep-Oct;76(5):477-478. doi: 10.1016/j.therap.2019.12.007.
     
  6. Vabre C, Araujo M, Damase-Michel C, Hurault-Delarue C, Lacroix I. Initial data on the safety of metopimazine during pregnancy and the risk of major birth defects and pregnancy loss - An observational study using the EFEMERIS database. Therapie. 2021 Oct 7:S0040-5957(21)00203-1. doi: 10.1016/j.therap.2021.09.006. Epub ahead of print.
2020
  1. Araujo M, Hurault-Delarue C, Sommet A, Damase-Michel C, Benevent J, Lacroix I. Drug prescriptions in French pregnant women between 2015 and 2016: A study in the EGB database. Therapie. 2021 May-Jun;76(3):239-247. . doi: 10.1016/j.therap.2020.07.002.
     
  2. Bénard-Laribière A, Pambrun E, Sutter-Dallay AL, Gautier S, Hurault-Delarue C, Damase-Michel C, Lacroix I, Pariente A. Impact of pregnancy on antidepressant treatment course: a population-based comparative cohort study in France. Arch Womens Ment Health. 2020 Oct;23(5):699-707. doi: 10.1007/s00737-020-01033-z.
     
  3. Cadoret F, Brazet E, Sartor A, Lacroix I, Casper C, Decramer S, Parant O. Unusual fetal ascites and spontaneous bladder rupture in a female fetus: a case report. J Med Case Rep. 2020 Jul 19;14(1):115. doi: 10.1186/s13256-020-02425-6.
     
  4. Lacroix I, Bénévent J, Damase-Michel C. Chloroquine and hydroxychloroquine during pregnancy: What do we know? Therapie. 2020 Jul-Aug;75(4):384-385. doi: 10.1016/j.therap.2020.05.004.
2019
  1. Araujo M, Hurault-Delarue C, Bouilhac C, Petiot D, Benevent J, Vayssière C, Vidal S, Montastruc JL, Damase-Michel C, Lacroix I. Non-steroidal anti-inflammatory drug prescriptions from the 6th month of pregnancy: impact of advice from health authorities. Fundam Clin Pharmacol. 2019 Oct;33(5):581-588. doi: 10.1111/fcp.12460.
     
  2. Benevent J, Araujo M, Hurault-Delarue C, Montastruc JL, Sommet A, Lacroix I, Damase-Michel C.  Pharmacoepidemiology in pregnancy. Therapie. 2019 Apr;74(2):289-300. doi: 10.1016/j.therap.2018.11.014.
     
  3. Benevent J, Hurault-Delarue C, Araujo M, Montastruc F, Montastruc JL, Lacroix I, Damase-Michel C.  Higher intake of medications for digestive disorders in children prenatally exposed to drugs with atropinic properties. Fundam Clin Pharmacol. 2019 Jun;33(3):314-326. doi: 10.1111/fcp.12428
     
  4. Benevent J, Hurault-Delarue C, Araujo M, Montastruc JL, Lacroix I, Damase-Michel C.  POMME: The New Cohort to Evaluate Long-Term Effects After Prenatal Medicine Exposure. Drug Saf. 2019 Jan;42(1):45-5 doi: 10.1007/s40264-018-0712-9.